Protalix BioTherapeutics shareholders approve increase in authorized common shares from 144M to 185M

Protalix BioTherapeutics, Inc.

Amendment to Certificate of Incorporation approved at reconvened 2023 Annual Meeting on July 13, 2023.
Authorized common shares increased by 41M, from 144M to 185M.
Votes: 33,870,055 for, 9,479,063 against, 1,042,433 abstentions.
Proposal passed with approximately 76% of votes cast in favor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.